Literature DB >> 12165372

An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia.

S Z East1, P W J Burnet, R W Kerwin, P J Harrison.   

Abstract

5-Hydroxytryptamine (5-HT; serotonin) 5-HT(6) receptors (5-HT(6)R) and 5-HT(7) receptors (5-HT(7)R) have been implicated in schizophrenia and as targets of atypical antipsychotic drugs. We have studied the expression of these receptors in the hippocampal formation and dorsolateral prefrontal cortex (DLPFC) of 17 subjects with schizophrenia and 17 controls using reverse transcription-polymerase chain reaction (RT-PCR) with cyclophilin co-amplification. In schizophrenia, 5-HT(6)R mRNA was decreased in the hippocampal formation, and 5-HT(7)R mRNA was decreased in the dorsolateral prefrontal cortex. The mRNAs were unchanged in rats treated for 2 weeks with haloperidol, chlorpromazine, risperidone, olanzapine or clozapine. Regional decreases in 5-HT(6)R and 5-HT(7)R expression in schizophrenia may contribute to the overall serotonergic alterations which occur in the disorder, in part through their interactions with other neurotransmitter systems including glutamate and acetylcholine. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165372     DOI: 10.1016/s0920-9964(01)00323-1

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

Review 2.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 3.  Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.

Authors:  Anne Matthys; Guy Haegeman; Kathleen Van Craenenbroeck; Peter Vanhoenacker
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

4.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

5.  Neuronal differentiation: 5-HT6R can do it alone.

Authors:  Jinsoo Seo; Li-Huei Tsai
Journal:  Nat Chem Biol       Date:  2014-07       Impact factor: 15.040

Review 6.  The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.

Authors:  Herbert Y Meltzer; Masakuni Horiguchi; Bill W Massey
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

7.  Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.

Authors:  Minako Tajiri; Atsuko Hayata-Takano; Kaoru Seiriki; Katsuya Ogata; Keisuke Hazama; Norihito Shintani; Akemichi Baba; Hitoshi Hashimoto
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

Review 8.  The 5-HT7 receptor and disorders of the nervous system: an overview.

Authors:  Peter B Hedlund
Journal:  Psychopharmacology (Berl)       Date:  2009-08-01       Impact factor: 4.530

Review 9.  Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.

Authors:  Agnieszka Nikiforuk
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

Review 10.  Cellular mechanisms of the 5-HT7 receptor-mediated signaling.

Authors:  Daria Guseva; Alexander Wirth; Evgeni Ponimaskin
Journal:  Front Behav Neurosci       Date:  2014-10-01       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.